American Association for Cancer Research
15357163mct180945-sup-207397_3_supp_5360002_ppmsj1.docx (626.45 kB)

Supplementary Figure S1 from The RNA-Binding Protein HuR Confers Oxaliplatin Resistance of Colorectal Cancer By Upregulating CDC6

Download (626.45 kB)
journal contribution
posted on 2023-04-03, 15:27 authored by Jian Cai, Huaiming Wang, Xiaodong Jiao, Rongkang Huang, Qiyuan Qin, Jianwei Zhang, Honglei Chen, Dan Feng, Xin Tian, Hui Wang

TMA-HuR expression by IHC.


Natural Science Foundation of Guangdong Province

Medical Science and Technology Research Foundation of Guangdong Province of China



Human antigen R (HuR) is an RNA-binding protein that posttranscriptionally regulates many cancer-trait genes. CDC6, a central regulator of DNA replication, is regulated by HuR. In this study, we investigated the role of HuR in colorectal cancer tumorigenesis and oxaliplatin (L-OHP) resistance, as well as the underlying mechanisms involving CDC6. We detected increased HuR and CDC6 expression, along with a positive correlation between the two in human colorectal cancer tissues. HuR overexpression increased colorectal cancer cell proliferation in vitro and xenograft tumor growth in vivo, and induced resistance to L-OHP. In contrast, HuR knockdown sensitized colorectal cancer cells to L-OHP. CDC6 overexpression increased while CDC6 knockdown decreased colorectal cancer cell malignant behaviors (growth, DNA synthesis, EMT, migration, and invasion) and L-OHP resistance in vitro. Moreover, L-OHP resistance induced by HuR overexpression was reversed by CDC6 knockdown. Mechanistically, the results from our luciferase reporter and ribonucleoprotein immunoprecipitation assays indicated that HuR upregulates CDC6 by binding to CDC6 3′-UTR. Taken together, our findings identified HuR's regulation of CDC6 as an essential mechanism driving colorectal cancer tumorigenesis and L-OHP resistance, and this mechanism may represent a potential target for overcoming drug resistance in colorectal cancer.

Usage metrics

    Molecular Cancer Therapeutics



    Ref. manager